Recurrent Pregnancy Loss

Derbala Reproductive Immunology > Recurrent Pregnancy Loss
Website image RPL

Understanding Recurrent Pregnancy Loss (RPL): Causes, Diagnosis, and Hope

Losing a pregnancy is one of the most heartbreaking experiences a couple can face. When it happens repeatedly, it can feel overwhelming and isolating. Recurrent Pregnancy Loss (RPL)—defined as two or more losses—affects approximately 2% to 5% of couples.

At our practice, we are dedicated to moving beyond the “unexplained” label. We believe in a proactive approach, investigating the whole picture—including the complex role of the immune system—from your very first consultation.

Why Does It Happen?

RPL is rarely caused by a single factor. In most cases, it is “multifactorial,” meaning several elements may be working together. Our comprehensive evaluation looks at all of the following:

1. Immunological Factors: The “Hidden Player”

For a pregnancy to succeed, the mother’s immune system must perform a biological miracle: it must recognize the embryo (which contains “foreign” genetic material from the father) and choose to protect it rather than reject it.

  • Natural Killer (NK) Cells (Peripheral vs. Uterine): It is vital to distinguish between the NK cells in your bloodstream (Peripheral) and those in your uterine lining (Uterine).
    • Peripheral NK cells: A high percentage of NK cells in the blood (typically cited as >12% or >15% depending on the lab) has been associated with an increased risk of miscarriage. A higher systemic count often reflects a “pro-inflammatory” state. If the systemic immune system is “primed” for a high-intensity response, it is more likely that the local uterine environment will also struggle to maintain the necessary state of tolerance required to accept an embryo. Perhaps more important than the number of cells is how active they are. This is known as cytotoxicity. In some women with RPL, the pNK cells are “hyper-reactive.” Studies have shown that women with high pNK cytotoxicity have a significantly lower live birth rate in subsequent untreated pregnancies. High cytotoxicity suggests that the immune system’s “killing” mechanism is easily triggered, which may correlate with an increased Th1 (pro-inflammatory) response.
    • Uterine NK cells are specialized helpers; they remodel blood vessels to nourish the placenta.
    • However, if either population is overactive or if the uterine density is too high, it can lead to a hostile environment for the embryo. We test both to get a complete picture of your systemic and localized immune status.
  • The Th1/Th2 Intracellular Cytokine Balance: In a healthy pregnancy, the body undergoes a “Th2 shift.” Th2 cytokines are anti-inflammatory and protective of the pregnancy. If the immune system remains “Th1-dominant,” it produces pro-inflammatory cytokines that can be toxic to the embryo and disrupt the implantation process.

2. Chromosomal & Genetic Factors

Frequently, an embryo has an abnormal number of chromosomes (aneuploidy), preventing normal development. While this is more common as we age, in some couples, one partner may carry a “balanced rearrangement” of chromosomes that increases the risk.

3. Antiphospholipid Syndrome (APS) & Systemic Autoimmunity

Autoimmunity occurs when the immune system mistakenly targets the body’s own tissues, creating a state of chronic inflammation that can be “silent” but highly impactful. Antiphospholipid Syndrome (APS) is the most well-known autoimmune cause of RPL, found in approximately 15% of cases; it involves antibodies that disrupt blood flow to the placenta and can be successfully managed with aspirin and heparin. However, we look beyond APS to include Thyroid Autoimmunity (such as TPO or TG antibodies) and Rheumatic Diseases antibodies (like Lupus, Rheumatoid Arthritis, or Sjögren’s Syndrome). Even if your thyroid hormones or rheumatic symptoms seem “well-managed,” the presence of autoantibodies or a positive Antinuclear Antibody (ANA) test suggests that your immune system is in a heightened “alert” mode. This systemic inflammation often drives a Th1-dominant pro-inflammatory state and elevates TNF-alpha levels, which can be toxic to a developing embryo. By identifying these “hidden” autoimmune triggers during our initial comprehensive workup, we can use targeted immunomodulators to quiet the systemic “noise” and ensure your body is in a state of tolerance before you conceive.

4. Uterine Environment & Anatomy

The shape of the uterus and the health of its lining are critical.

  • Anatomy: Uterine septums, fibroids, or scar tissue can interfere with implantation.
  • Chronic Endometritis: This is a persistent, low-grade inflammation of the uterine lining. It is a key focus of our specialized testing.

5. Hormonal & Metabolic Factors

Uncontrolled thyroid disease, diabetes, elevated prolactin, and Polycystic Ovary Syndrome (PCOS) can all disrupt the delicate hormonal balance required to maintain a pregnancy.

6. Inherited Thrombophilia (Blood Clotting Disorders)

Some women carry genetic variations that make their blood more prone to clotting. Common inherited thrombophilias include Factor V Leiden, Prothrombin G20210A mutation, and Protein C, Protein S, or Antithrombin III deficiencies.

  • The Link to RPL: These conditions can potentially lead to microscopic blood clots at the site where the placenta attaches to the uterus, cutting off oxygen and nutrients to the embryo.  

Our Comprehensive Evaluation: No Stone Unturned

Unlike standard protocols that may test in “stages” over many months, we believe in a comprehensive, all-at-once evaluation. By performing the immunological workup alongside standard testing, we provide answers faster.

Our core immunological evaluation includes:

  • Immune Profiling: Assessing NK cells (in uterus and blood) and cytokine profiling.
  • Autoimmune panel
  • Thrombophilia testing
  • Hysteroscopic evaluation of the uterine cavity
  • Metabolic and hormonal evaluation
  • Ultrasound evaluation: evaluating the uterus and ovaries (including the blood flow).

Treatment Pathways: Personalizing Your Care

Because we evaluate all factors simultaneously—from specialized immune markers to standard fertility indicators—we don’t rely on a “one size fits all” approach. Instead, we formulate an individualized protocol tailored to your unique results. Depending on your specific profile, your plan may include:

  • Immunomodulation: Utilizing targeted therapies (such as Prednisone,Tacrolimus, Plaquenil or IVIG) to calm pro-inflammatory responses and foster a protective environment for the embryo.
  • Blood Flow & Clotting Support: Addressing autoimmune (APS) or inherited clotting factors with specialized protocols, often involving low-dose aspirin or heparin, to ensure healthy placental development.
  • Systemic & Hormonal Optimization: Optimizing thyroid and metabolic health to lower systemic inflammation and create the ideal conditions for conception.
  • Nutraceutical Support: We incorporate specific supplements to reduce oxidative stress, improve egg quality, and prime the immune system for a state of tolerance before conception.

Our goal is to shift your body from a state of “defense” to a state of “nurture,” providing the precise support needed for a healthy, full-term pregnancy.

There Is Reason for Hope

Despite the pain of repeated losses, the prognosis for most couples is remarkably bright. Depending on your age and history, the chance of a successful future pregnancy ranges from 50% to 90%.

By identifying the “why” through a deep dive into reproductive immunology and standard fertility markers simultaneously, we remove the guesswork and create a clear path toward bringing your baby home.

 

References:

  1. Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent Pregnancy Loss. Nature Reviews Disease Primers. 2020;6(1):98. doi:10.1038/s41572-020-00228-z
  2. Quenby S, Gallos ID, Dhillon-Smith RK, et al. Miscarriage Matters: The Epidemiological, Physical, Psychological, and Economic Costs of Early Pregnancy Loss. Lancet. 2021;397(10285):1658-1667. doi:10.1016/S0140-6736(21)00682-6
  3. Coomarasamy A, Dhillon-Smith RK, Papadopoulou A, et al. Recurrent Miscarriage: Evidence to Accelerate Action. Lancet. 2021;397(10285):1675-1682. doi:10.1016/S0140-6736(21)00681-4
  4. Motan T, Cockwell H, Elliott J, et al. Guideline No. 464: Recurrent Pregnancy Loss. Journal of Obstetrics and Gynaecology Canada. 2025;:103167. doi:10.1016/j.jogc.2025.103167
  5. Guerrero B, Hassouneh F, Delgado E, Casado JG, Tarazona R. Natural Killer Cells in Recurrent Miscarriage: An Overview. Journal of Reproductive Immunology. 2020;142:103209. doi:10.1016/j.jri.2020.103209
  6. Guan D, Chen Z, Zhang Y, et al. Dual Role of Natural Killer Cells in Early Pregnancy: Immunopathological Implications and Therapeutic Potential in Recurrent Spontaneous Abortion and Recurrent Implantation Failure. Cell Proliferation. 2025;:e70037. doi:10.1111/cpr.70037 
  7. Dosiou C, Giudice LC. Natural Killer Cells in Pregnancy and Recurrent Pregnancy Loss: Endocrine and Immunologic Perspectives. Endocrine Reviews. 2005;26(1):44-62. doi:10.1210/er.2003-0021
  8. Rai R, Regan L. Recurrent Miscarriage. Lancet. 2006;368(9535):601-11. doi:10.1016/S0140-6736(06)69204-0
  9. Andreescu M, Frîncu F, Plotogea M, Mehedințu C. Recurrent Abortion and the Involvement of Killer-Cell Immunoglobulin-Like Receptor (KIR) Genes, Activated T Cells, NK Abnormalities, and Cytokine Profiles. Journal of Clinical Medicine. 2023;12(4):1355. doi:10.3390/jcm12041355
  10. Woon EV, Nikolaou D, MacLaran K, et al. Uterine NK Cells Underexpress KIR2DL1/S1 and LILRB1 in Reproductive Failure. Frontiers in Immunology. 2022;13:1108163. doi:10.3389/fimmu.2022.1108163
  11. Wang W, Sung N, Gilman-Sachs A, Kwak-Kim J. T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/TFH Cells. Frontiers in Immunology. 2020;11:2025. doi:10.3389/fimmu.2020.02025
  12. Piccinni MP, Raghupathy R, Saito S, Szekeres-Bartho J. Cytokines, Hormones and Cellular Regulatory Mechanisms Favoring Successful Reproduction. Frontiers in Immunology. 2021;12:717808. doi:10.3389/fimmu.2021.717808
  13. AbdulHussain G, Azizieh F, Makhseed M, Raghupathy R. Effects of Progesterone, Dydrogesterone and Estrogen on the Production of Th1/Th2/Th17 Cytokines by Lymphocytes From Women With Recurrent Spontaneous Miscarriage. Journal of Reproductive Immunology. 2020;140:103132. doi:10.1016/j.jri.2020.103132
  14. Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid Syndrome. Obstetrics and Gynecology. 2012;120(6):1514-21. doi:10.1097/01.AOG.0000423816.39542.0f
  15. Hamulyák EN, Scheres LJJ, Goddijn M, Middeldorp S. Antithrombotic Therapy to Prevent Recurrent Pregnancy Loss in Antiphospholipid Syndrome—What Is the Evidence? Journal of Thrombosis and Haemostasis. 2021;19(5):1174-1185. doi:10.1111/jth.15290
  16. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology. 2020;72(4):529-556. doi:10.1002/art.41191
  17. Dong AC, Morgan J, Kane M, Stagnaro-Green A, Stephenson MD. Subclinical Hypothyroidism and Thyroid Autoimmunity in Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Fertility and Sterility. 2020;113(3):587-600.e1. doi:10.1016/j.fertnstert.2019.11.003
  18. Blomqvist L, Nyström HF, Hellgren M, Strandell A. Preconceptual Thyroid Peroxidase Antibody Positivity in Women With Recurrent Pregnancy Losses May Contribute to an Increased Risk for Another Miscarriage. Clinical Endocrinology. 2023;98(2):259-269. doi:10.1111/cen.14825
  19. Subclinical Hypothyroidism in the Infertile Female Population: A Guideline. Fertility and Sterility. 2024;121(5):765-782. doi:10.1016/j.fertnstert.2023.12.038
  20. Liu X, Chen Y, Ye C, et al. Hereditary Thrombophilia and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Human Reproduction. 2021;36(5):1213-1229. doi:10.1093/humrep/deab010
  21. Quenby S, Booth K, Hiller L, et al. Heparin for Women With Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An International Open-Label, Randomised Controlled Trial. Lancet. 2023;402(10395):54-61. doi:10.1016/S0140-6736(23)00693-1
  22. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstetrics and Gynecology. 2018;132(1):e18-e34. doi:10.1097/AOG.0000000000002703
  23. Grandone E, Piazza G. Thrombophilia, Inflammation, and Recurrent Pregnancy Loss: A Case-Based Review. Seminars in Reproductive Medicine. 2021;39(1-02):62-68. doi:10.1055/s-0041-1731827
  24. Ticconi C, Inversetti A, Marraffa S, et al. Chronic Endometritis and Recurrent Reproductive Failure: A Systematic Review and Meta-Analysis. Frontiers in Immunology. 2024;15:1427454. doi:10.3389/fimmu.2024.1427454
  25. Pirtea P, Cicinelli E, De Nola R, de Ziegler D, Ayoubi JM. Endometrial Causes of Recurrent Pregnancy Losses: Endometriosis, Adenomyosis, and Chronic Endometritis. Fertility and Sterility. 2021;115(3):546-560. doi:10.1016/j.fertnstert.2020.12.010
  26. McQueen DB, Maniar KP, Hutchinson A, et al. Redefining Chronic Endometritis: The Importance of Endometrial Stromal Changes. Fertility and Sterility. 2021;116(3):855-861. doi:10.1016/j.fertnstert.2021.04.036
  27. Popescu F, Jaslow CR, Kutteh WH. Recurrent Pregnancy Loss Evaluation Combined With 24-Chromosome Microarray of Miscarriage Tissue Provides a Probable or Definite Cause of Pregnancy Loss in Over 90% of Patients. Human Reproduction. 2018;33(4):579-587. doi:10.1093/humrep/dey021
  28. Klimczak AM, Patel DP, Hotaling JM, Scott RT. Role of the Sperm, Oocyte, and Embryo in Recurrent Pregnancy Loss. Fertility and Sterility. 2021;115(3):533-537. doi:10.1016/j.fertnstert.2020.12.005
  29. Mumusoglu S, Telek SB, Ata B. Preimplantation Genetic Testing for Aneuploidy in Unexplained Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Fertility and Sterility. 2025;123(1):121-136. doi:10.1016/j.fertnstert.2024.08.326
  30. The Use of Preimplantation Genetic Testing for Aneuploidy: A Committee Opinion. Fertility and Sterility. 2024;122(3):421-434. doi:10.1016/j.fertnstert.2024.04.013
  31. Coomarasamy A, Devall AJ, Brosens JJ, et al. Micronized Vaginal Progesterone to Prevent Miscarriage: A Critical Evaluation of Randomized Evidence. American Journal of Obstetrics and Gynecology. 2020;223(2):167-176. doi:10.1016/j.ajog.2019.12.006
  32. Haas DM, Bofill Rodriguez M, Hathaway TJ, Ramsey PS. Progestogen for Preventing Miscarriage in Women With Recurrent Miscarriage of Unclear Etiology. Cochrane Database of Systematic Reviews. 2025;6:CD003511. doi:10.1002/14651858.CD003511.pub6
  33. Yang X, Meng T. Is There a Role of Intravenous Immunoglobulin in Immunologic Recurrent Pregnancy Loss? Journal of Immunology Research. 2020;2020:6672865. doi:10.1155/2020/6672865
  34. Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, et al. Effect of Intravenous Immunoglobulin on Th1 and Th2 Lymphocytes and Improvement of Pregnancy Outcome in Recurrent Pregnancy Loss (RPL). Biomedicine & Pharmacotherapy. 2017;92:1095-1102. doi:10.1016/j.biopha.2017.06.001
  35. Cavalcante MB, Alcântara da Silva PH, Sampaio OGM, et al. The Use of Immunotherapies for Recurrent Miscarriage: An Overview of Systematic Reviews and Meta-Analysis. Journal of Reproductive Immunology. 2023;158:103986. doi:10.1016/j.jri.2023.103986
  36. Han JW, Park JS, Kim JS, Lee SK. Efficacy of Intravenous Immunoglobulin in Recurrent Pregnancy Loss: A Retrospective Analysis of Patients With Abnormal Cellular Immunity. Frontiers in Endocrinology. 2025;16:1546602. doi:10.3389/fendo.2025.1546602
  37. Meng S, Zhang T, Li C, Zhang X, Shen H. Immunoregulatory Therapy Improves Reproductive Outcomes in Elevated Th1/Th2 Women With Embryo Transfer Failure. BioMed Research International. 2022;2022:4990184. doi:10.1155/2022/4990184
  38. Gavillet M, Gengler C, Legardeur H, et al. Case Report: A Novel Approach to Prevent Chronic Histiocytic Intervillositis and Recurrent Pregnancy Loss by Targeting Maternal Alloimmunity. Frontiers in Immunology. 2025;16:1693016. doi:10.3389/fimmu.2025.1693016
  39. The Role of Immunotherapy in In Vitro Fertilization: A Guideline. Fertility and Sterility. 2018;110(3):387-400. doi:10.1016/j.fertnstert.2018.05.009
  40. Liu M, Zhen X, Song H, et al. Low-Dose Lymphocyte Immunotherapy Rebalances the Peripheral Blood Th1/Th2/Treg Paradigm in Patients With Unexplained Recurrent Miscarriage. Reproductive Biology and Endocrinology. 2017;15(1):95. doi:10.1186/s12958-017-0315-9
  41. Society for Maternal-Fetal Medicine (SMFM). Consult Series #64: Systemic Lupus Erythematosus in Pregnancy. American Journal of Obstetrics and Gynecology. 2023;228(3):B41-B60. doi:10.1016/j.ajog.2022.09.001
  42. Zhao SJ, Muyayalo KP, Luo J, et al. Next Generation of Immune Checkpoint Molecules in Maternal-Fetal Immunity. Immunological Reviews. 2022;308(1):40-54. doi:10.1111/imr.13073
  43. Coomarasamy A, Gallos ID, Papadopoulou A, et al. Sporadic Miscarriage: Evidence to Provide Effective Care. Lancet. 2021;397(10285):1668-1674. doi:10.1016/S0140-6736(21)00683-8
  44. Li S, Zheng PS, Ma HM, et al. Systematic Review of Subsequent Pregnancy Outcomes in Couples With Parental Abnormal Chromosomal Karyotypes and Recurrent Pregnancy Loss. Fertility and Sterility. 2022;118(5):906-914. doi:10.1016/j.fertnstert.2022.08.008
  45. Kutteh WH, Papas RS, Maisenbacher MK, Dahdouh EM. Role of Genetic Analysis of Products of Conception and PGT in Managing Early Pregnancy Loss. Reproductive Biomedicine Online. 2024;49(1):103738. doi:10.1016/j.rbmo.2023.103738
Back